Nuformix PLC Dr Andy Richards Chairs Advisory Panel - New Appts (3000Z)
14 December 2017 - 6:01PM
UK Regulatory
TIDMNFX
RNS Number : 3000Z
Nuformix PLC
14 December 2017
Nuformix plc
("Nuformix" or "the Company")
Advisory Panel Appointments
Chaired by Dr Andy Richards
Nuformix, the pharmaceutical development company using cocrystal
technology to unlock the therapeutic potential of approved small
molecule drugs, announces the following appointments to its
Advisory Panel, with immediate effect:
Dr Andy Richards CBE - appointed Chairman, Advisory Panel. Andy
is Chairman of Congenica, Arecor, and Abcodia, and is a director of
Silence Therapeutics plc, Ieso Digital Health, Sensiia, and Cancer
Research Technology (commercial arm of CR-UK). He is Chair of the
Babraham Research Campus and was until recently a non-executive
director of Cambridge University Hospitals Trust.
His early career spanned positions with ICI (now AstraZeneca)
and PA Technology, and he was a founder and executive director of
Chiroscience. Since 1999 he has founded, invested in and helped to
scale innovative UK based biotechnology and healthcare companies,
with more than 25 ventures over the last 16 years. These include
companies such as Vectura, Arakis, Cambridge Biotechnology Ltd and
Geneservice. Andy is also a founder member of the Cambridge Angels,
and was awarded a CBE in 2015 for services to life-science
investment.
Prof Derek Mann - Nuformix has been working with Derek and his
team to further validate NFX002, the Nuformix fibrosis programme.
Derek will continue to advise the Nuformix team in pre-clinical
fibrosis research.
He is Director of the Newcastle Fibrosis Research Group (NFRG),
which is focussed on developing translational solutions to tissue
remodelling and scar formation in the liver, lung, kidneys, heart
and skin. Derek's research group is primarily interested in
understanding the molecular basis for liver fibrosis (scarring) and
primary liver cancer. Recent discoveries include mechanisms of
transgenerational epigenetic inheritance affecting fibrosis and a
role for inflammatory neutrophils in hepatocellular carcinoma.
At the NFRG he has developed a number of collaborative strategic
alliances with major pharmaceutical companies including GSK and
Abbvie, which are aimed at translation of the NFRG research to the
design of fibrosis biomarkers and new therapeutics. He is also the
Dean of Research and Innovation in the Faculty of Medical Sciences
at Newcastle University.
Dr Paul Goldsmith - Paul joins the Advisory Panel. He is a
commercial medic with experience founding and building both drug
and digital health companies and is now co-leading the development
of Closed Loop Medicine Ltd. He is a Consultant Neurologist,
trained in Cambridge, Oxford, London and Newcastle. His insights
into the translational clinical-commercial interface will be
invaluable to Nuformix.
Commenting, Dr Andy Richards, said: "Co-crystallisation is a
broadly applicable technology with much promise for modulating,
improving and differentiating the properties of both new and known
drug molecules. Nuformix is a world leader in the application of
this approach, with a proven track record. I am excited about
working with the team and with the Advisory Panel to further
product developments that can benefit patients."
Commenting, Dr Dan Gooding, Chief Executive Officer, Nuformix,
said: "Cementing our Advisory Panel was a key business objective
post RTO-completion. This World-class team offers specific
expertise relating to the delivery of key NFX activities and will
evolve as the Company progresses. We've worked with Andy Richards
for several years - it's difficult to find anyone more experienced
in understanding the technical and commercial challenges in
developing and commercialising products based on known drugs. We've
also been working with Derek Mann and his NFRG team - currently one
of the World's leading centres for conducting fibrosis research.
Derek will guide us as we perform innovative, close-to-patient
studies as we prepare to take NXP002 into the clinic. Paul
Goldsmith brings invaluable experience of the real world
clinical-commercial interface, in the context of the needs of a
company such as Nuformix. Chaired by Dr Andy Richards, the Advisory
Panel provides us with a wealth of technical and commercial
understanding alongside corporate experience."
Follow Nuformix on Vox Markets: follow at
www.voxmarkets.co.uk/company/NFX
and www.nuformix.com
Market Abuse Regulation (MAR) Disclosure. Certain information
contained in this announcement would have been deemed inside
information for the purposes of Article 7 of Regulation (EU) No
596/2014 until the publication of this announcement via a
Regulatory Information Service and accordingly, this inside
information is now considered to be in the public domain.
ENDS
Enquiries:
Nuformix plc
Dr Dan Gooding, Chief Executive +44 (0)1223
Officer 423667
Beaufort Securities Limited
(Broker) +44 (0)20 7382
Jon Belliss 8300
Gable Communications Ltd +44 (0)20 7193
John Bick / Justine James 7463
About Nuformix plc www.nuformix.com
Nuformix is a pharmaceutical development company using cocrystal
technology to unlock the therapeutic potential of approved small
molecule drugs. Nuformix' risk-mitigated development strategy has
resulted in a pipeline of discoveries through which it has
developed and patented novel cocrystal forms of approved small
molecules.
Nuformix has created an IP portfolio containing a range of
granted patents covering cocrystal forms of five small molecule
drugs. Nuformix is targeting high-value unmet needs with its lead
programmes in oncology supportive care: NXP001 and fibrosis:
NXP002.
Nuformix was established in Cambridge in 2008 and has invested
into pharmaceutical cocrystal R&D, establishing world-class
capability and know-how in cocrystal discovery and development,
yielding multiple product opportunities. Nuformix plc shares are
traded on the London Stock Exchange's Official List under the
ticker: NFX.L.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCOKNDKBBDBCBD
(END) Dow Jones Newswires
December 14, 2017 02:01 ET (07:01 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Apr 2024 to May 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From May 2023 to May 2024